Diego
Serrano Tejero
Colaborador Docente
Diego Serrano Tejero-rekin lankidetzan egindako argitalpenak (8)
2023
-
PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
Cancer Research, Vol. 83, Núm. 15, pp. 2513-2526
2022
-
Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma
DMM Disease Models and Mechanisms, Vol. 15, Núm. 1
-
YES1 Is a Druggable Oncogenic Target in SCLC
Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1387-1403
2021
-
Circulating levels of the interferon-γ-regulated chemokines cxcl10/cxcl11, il-6 and hgf predict outcome in metastatic renal cell carcinoma patients treated with antiangiogenic therapy
Cancers, Vol. 13, Núm. 11
-
Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 9
-
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3
2013
-
Epithelial to mesenchymal transition and cancer stem cell phenotypes leading to liver metastasis are abrogated by the novel TGFΒ1-targeting peptides P17 and P144
Experimental Cell Research, Vol. 319, Núm. 3, pp. 12-22
2009
-
The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer
British Journal of Cancer, Vol. 100, Núm. 6, pp. 932-940